Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.

Employees

Sector

Biotechnology & Medical Research

More about the company

07-14	Top Premarket Decliners	MT
07-13	Azurity Pharmaceuticals, Inc. entered into the stock purchase agreement to acquire Matinas Biopharma Nanotechnologies, Inc. from Matinas BioPharma Holdings, Inc. (NYSEAM : MTNB) for $21.5 million.	CI

Market Cap	2.2M 1.92M 1.78M 1.64M 3.08M 212M 3.15M 21.22M 8.34M 104M 8.27M 8.09M 357M	P/E 2024	-0.1x	P/E 2025	-0.29x
Enterprise Value	-444K -388K -358K -330K -622K -42.74M -636K -4.28M -1.68M -20.93M -1.67M -1.63M -72.06M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	81.97%	Yield 2024 *	-	Yield 2025	-

07-14	Top Premarket Decliners	MT
07-13	Azurity Pharmaceuticals, Inc. entered into the stock purchase agreement to acquire Matinas Biopharma Nanotechnologies, Inc. from Matinas BioPharma Holdings, Inc. (NYSEAM : MTNB) for $21.5 million.	CI
07-13	Matinas BioPharma to Merge With GH Power; Signs Deal to Sell Subsidiary, Lead Product Candidate	MT
06-16	Matinas BioPharma Files $150 Million Mixed Shelf Registration	MT
05-08	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Matinas BioPharma Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI
01-23	Matinas BioPharma Holdings Inc Keith Kucinski resigns as CFO effective January 17, 2026	RE
01-23	Jerome D. Jabbour to Assume the Duties of Principal Accounting Officer of Matinas BioPharma Holdings, Inc	CI
01-23	Matinas Biopharma Holdings, Inc. Appoints Jerome D. Jabbour as Interim Chief Financial Officer, Effective January 22, 2026	CI
11-21	Matinas Biopharma Holdings Inc - CFO Keith Kucinski resigns effective January 17, 2026 - SEC filing	RE
11-21	Matinas BioPharma Holdings, Inc. Announces Resignation of Keith Kucinski as Chief Financial Officer , Effective January 17, 2026	CI
11-10	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

24-10-31	Maxim Downgrades Matinas BioPharma to Hold From Buy	MT
21-05-11	MATINAS BIOPHARMA : Piper Sandler Cuts Matinas BioPharma Holdings to Neutral From Overweight, Price Target to $0.90 From $4	MT
21-03-30	MATINAS BIOPHARMA : HC Wainwright Adjusts Price Target on Matinas BioPharma Holdings to $3 From $4, Maintains Buy Rating	MT

07-13	GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma	BU
07-13	Matinas BioPharma : Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals	PU
07-13	Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals	AQ
06-26	Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance	AQ
04-06	Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards	AQ

Matinas BioPharma Holdings Inc Stock Other OTC

Stocks

US5768101058

Biotechnology & Medical Research

Valuation: Matinas BioPharma Holdings Inc

Latest news : Matinas BioPharma Holdings Inc

Analysts' recommendations: Matinas BioPharma Holdings Inc

Press Releases: Matinas BioPharma Holdings Inc

Managers and Directors: Matinas BioPharma Holdings Inc

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Jerome Jabbour CEO	Chief Executive Officer	52	2018-03-15
Susan Johansson CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Jerome Jabbour CHM	Chairman	52	2025-03-13
Evelyn D'An BRD	Director/Board Member	61	2025-02-04
Keith Murphy BRD	Director/Board Member	55	2025-03-10

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-7.17%	-4.39%	+45.51%	+79.00%	52.1B
ARGENX SE	+0.24%	-1.54%	+53.22%	+71.85%	53.83B
INSMED INCORPORATED	+0.80%	-6.31%	+3.98%	+423.29%	23.48B
BIONTECH SE	-0.09%	-0.01%	-17.62%	-14.67%	23.13B
WUXI BIOLOGICS (CAYMAN) INC.	-5.95%	-2.58%	+30.67%	-9.58%	19.36B
GENMAB A/S	-1.14%	+0.03%	+31.57%	-30.42%	17.56B
PHARMAESSENTIA CORPORATION	-5.16%	-7.00%	+168.44%	+306.37%	15.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.91%	-5.83%	+26.53%	+636.97%	14.83B
EXELIXIS, INC.	+0.43%	-1.03%	+24.63%	+191.40%	14.06B
Average	-2.77%	-2.62%	+40.77%	+183.80%	25.95B
Weighted average by Cap.	-2.80%	-2.36%	+40.12%	+144.11%

	2024	2025
Net sales	-	-
Net income	-24.25M -21.19M -19.56M -18.03M -33.98M -2.34B -34.73M -234M -91.94M -1.14B -91.07M -89.08M -3.94B	-10.34M -9.04M -8.34M -7.69M -14.49M -996M -14.82M -99.71M -39.22M -488M -38.85M -38M -1.68B
Net Debt	-4.39M -3.84M -3.54M -3.26M -6.15M -423M -6.29M -42.31M -16.64M -207M -16.49M -16.12M -713M	-2.64M -2.31M -2.13M -1.97M -3.71M -255M -3.79M -25.49M -10.03M -125M -9.93M -9.72M -429M

End-of-day quote Other OTC Other stock markets
- ^USD	-